Adult liver transplantation: A UK clinical guideline - part 1: pre-operation

Charles Millson,1 Aisling Considine,2 Matthew E Cramp,3 Andrew Holt,4 Stefan Hubscher,5 John Hutchinson,6 Kate Jones,7 Joanna Leithead,8 Steven Masson,9 Krish Menon,10 Darius Mirza,11 James Neuberger,12 Raj Prasad,13 Anthony Pratt,14 Wendy Prentice,15 Liz Shepherd,16 Ken Simpson,17 Doug Thorburn,18 Rachel Westbrook,19 Dhiraj Tripathi20

ABSTRACT
Liver transplantation is a highly successful treatment for all types of liver failure, some non-liver failure indications and liver cancer. Most referrals come from secondary care. This first part of a two-part guideline outlines who to refer, and how that referral should be made, including patient details and additional issues such as those relevant to alcohol and drug misuse. The process of liver transplant assessment involves the confirmation of the diagnosis and non-reversibility, an evaluation of comorbidities and exclusion of contraindications. Finally, those making it onto the waiting list require monitoring and optimising. Underpinning this process is a need for good communication between patient, their carers, secondary care and the liver transplant service, synchronised by the transplant coordinator. Managing expectation and balancing the uncertainty of organ availability against the inevitable progression of underlying liver disease requires sensitivity and honesty from all healthcare providers and the assessment of palliative care needs is an integral part of this process.

INTRODUCTION
Over just three decades, UK liver transplantation has evolved from the enthusiastic efforts of a few well-intentioned clinicians to a multidisciplinary, closely scrutinised therapy with 1-year survival rates in excess of 90%.

WHO TO REFER FOR LT

Over 90% of LTs in the UK are performed for CLD, where a gradual destruction of liver tissue results in the familiar picture of jaundice, ascites, encephalopathy with coagulopathy and hypoalbuminaemia. A smaller number will have ALF and an even smaller number are transplanted for a non-failing liver, where there is survival advantage. This section identifies the reasons, which should prompt either a referral to an LTU or mandate an enquiry.

Acute liver failure
While there are several ALF definitions, the critical elements for the purpose of this guideline, are the three cardinal features of encephalopathy, jaundice and coagulopathy appearing in a patient who, less than 6 months ago, had no evidence of advanced liver disease. The challenge for the generalist in an AMU or emergency department...
environment is establishing the diagnosis of severe liver injury quickly and minimising the delay in seeking help. Early discussions with LTU enable decisions on comorbidities or contraindications to LT (see below) to be addressed before hepatic encephalopathy develops and safe transfer becomes too high-risk.

Causes of ALF
Despite changes to packaging, paracetamol (acetaminophen) poisoning remains the most common cause for ALF in the UK. The next most common cause is non-A-to-E hepatitis, then other drug induced liver injuries (prescribed, herbal and proscribed), viral hepatitis and ischaemic hepatitis. Malignancy (primary or secondary), pregnancy (AFLP/HELLP), vascular (including Budd-Chiari Syndrome) and metabolic disorders are rarer causes.

Alcoholic hepatitis is considered in the CLD section, as is acute on chronic liver failure (AoCLF).

When to consider referral/discussion with the LTU in ALF
Once diagnosed, the ALF patient should be managed in an HDU environment and discussed with a LTU (see Table 1). Important details include any history of paracetamol ingestion (timing, frequency, ‘staggered’), pregnancy, other drugs (prescribed, herbal or proscribed), comorbidity (mental and physical health), laboratory results (including PT, pH, arterial lactate, glucose, renal function, viral screen, autoantibodies and immunoglobulins) and liver imaging. Ideally, patients are safer transferred before encephalopathy appears, although there is little published guidance covering this important aspect.

Table 1 outlines clinical features in paracetamol and non-paracetamol ALF that correlate with poor outcome and mandate referral. Rarely, non-paracetamol ALF, can present with ascites, deep jaundice and even variceal haemorrhage, where the short history remains the only clue to ALF.

Chronic liver failure
CLF occurs on the background of established liver cirrhosis. The typical clinical features include jaundice, ascites, encephalopathy, sarcopenia along with laboratory features, such as hypoalbuminaemia and coagulopathy, often associated with a rising creatinine and hyponatraemia as liver disease advances. Box 1 describes common causes of CLF.

Acute on chronic liver failure
Acute-on-chronic liver failure (AoCLF) is a syndrome characterised by acute decompensation of CLD associated with organ failures and high short-term mortality. Sepsis, active alcoholism and relapse of chronic viral hepatitis are the most common reported precipitating factors, but still only account for perhaps half the cases, the remainder have no identifiable trigger. The poor prognosis mimics that seen in ALF and mandates an expedited triage and consideration for LT. However, while LT remains the definitive treatment, sadly very few prove suitable.

When to consider referral/discussion with the LTU in CLF or AoCLF
Liver transplantation should be considered, when a patient with established liver disease develops any of the typical features of decompensation (Figure 1). As decompensation correlates with rising morbidity and mortality, the supervising clinician should reflect on the key considerations outlined below.

Table 1 When referral/discussion with the LTU is required for a patient with ALF

<table>
<thead>
<tr>
<th>Paracetamol induced acute liver failure</th>
<th>Non-paracetamol induced acute liver failure</th>
</tr>
</thead>
<tbody>
<tr>
<td>► Arterial pH &lt;7.30 or HCO₃ &lt;18 mmol/L</td>
<td>► pH &lt;7.30 or HCO₃ &lt;18 mmol/L</td>
</tr>
<tr>
<td>► INR &gt;3.0 on day two or &gt;4.0 thereafter</td>
<td>► INR &gt;1.8</td>
</tr>
<tr>
<td>► Oliguria and/or AKI</td>
<td>► Oliguria/renal failure or Na &lt;130 mmol/L</td>
</tr>
<tr>
<td>► Altered level of consciousness</td>
<td>► Encephalopathy, hypoglycaemia or metabolic acidosis</td>
</tr>
<tr>
<td>► Hypoglycaemia</td>
<td>► Bilirubin &gt;300 umol/L (17.6 mg/dL)</td>
</tr>
<tr>
<td>► Elevated arterial lactate (&gt;4 mmol/L)</td>
<td></td>
</tr>
</tbody>
</table>

AKI, acute kidney injury; ALF, acute liver failure; CLF, chronic liver failure; INR, international normalised ratio; LT, liver transplantation; LTU, liver transplant unit.

Causes of CLF:
- Alcohol.*
- Non-alcoholic fatty liver disease.
- Chronic viral hepatitis (B, C and D).
- Autoimmune liver disease (Primary Biliary Cholangitis, Primary Sclerosing Cholangitis, Autoimmune Hepatitis and overlap syndromes).
- Wilson’s disease.
- Genetic haemochromatosis.
- Alpha-1 antitrypsin deficiency.
- Secondary sclerosing cholangitis.
- Congenital hepatic fibrosis and other congenital or hereditary liver diseases.

*Alcoholic hepatitis tends to present acutely, frequently with no history of liver disease. Most patients recover with abstinence, but recent studies have demonstrated excellent outcomes with liver transplant in highly selected patients.
Key considerations in patients with hepatic decompensation

1. Is the decompensation potentially reversible (for example with abstinence in the case of ALD or with anti-virals in untreated chronic viral hepatitis)* or
2. If not reversible, is the patient suitable for LT*? or
3. Are there any contraindications to LT such as comorbidity which preclude transplant* (see table 5)?
4. If not currently suitable for transplant, could a patient become suitable with treatment or an intervention*?

*If in any doubt, seek advice from local LTU

Bear in mind that it is possible for a patient to be too unwell for LT if the referral is made too late.

To aid with the assessment of suitability for referral, the UK Model for End-Stage Liver Disease (UKELD) score can be calculated. The UKELD score is devised from patient’s INR, serum sodium, creatinine and bilirubin (https://www.odt.nhs.uk/transplantation/tools-policies-and-guidance/calculators/). UKELD scores ≥49 indicate survival advantage for LT over conservative management in patients with irreversible decompensation.

Patients with decompensated CLD, unsuitable for LT, should have this conclusion documented and receive symptom-directed care.

Non-liver failure indications for liver transplantation

Some patients will still benefit from LT, even though their liver is not failing (i.e., likely to cause death within 12 months). This would include patients with cirrhosis and a UKELD score under 49, such as PBC patients with intractable pruritus (see table 2). 5 6 8 15

HOW TO REFER FOR LT

The next step is referral to the nearest LTU (see online supplementary appendix 1). For ALF patients, a telephone referral is obligatory, but for all other indications, a written referral suffices. Email may speed the referral process, but correspondence with a named individual in LTU encourages collaborative dialogue between referring and transplant physicians. Most referrals for CLD patients come from secondary care hepatologists or gastroenterologists, but referrals are welcomed from any source in primary or secondary care.

What will the LTU want to know?

The LTU will require details of the primary liver disease and its complications, comorbidity, compliance issues, alcohol or drug misuse, family support, previous abdominal surgery and cancer.

A sample transplant assessment tool used is attached as online supplementary appendix 2, but shouldn’t replace a letter covering the above issues.

Table 2  Other aetiologies (non-liver failure) suitable for LT5 6 8 15

<table>
<thead>
<tr>
<th>Variant syndromes*</th>
<th>Hepatocellular carcinoma (HCC)†</th>
</tr>
</thead>
<tbody>
<tr>
<td>◀ Hepatopulmonary syndrome</td>
<td>▶ Up to 25% of liver transplants in UK have HCC</td>
</tr>
<tr>
<td>◀ Persistent and intractable pruritus</td>
<td>▶ Associated with most CLD (HBV, HCV, ALD, NAFLD, autoimmune liver disease, haemochromatosis) and Aflatoxin ingestion</td>
</tr>
<tr>
<td>◀ Polycystic liver disease</td>
<td>▶ Current LT selection criteria:</td>
</tr>
<tr>
<td>◀ Familial hyperlipidaemia</td>
<td>‒ Single tumour &lt;5 cm in diameter, or</td>
</tr>
<tr>
<td>◀ Recurrent cholangitis</td>
<td>‒ Up to five tumours all ≤3 cm, or</td>
</tr>
<tr>
<td>◀ Familial amyloidosis</td>
<td>‒ Single tumour &gt;5 cm and ≤7 cm in diameter if no progression over 6 months (larger HCC’s can be ‘downstaged’ by local therapies and then considered for transplantation)</td>
</tr>
<tr>
<td>◀ Hepatic epithelioid haemangioendothelioma</td>
<td>‒ AFP &lt;1000</td>
</tr>
<tr>
<td>◀ Nodular regenerative hyperplasia</td>
<td>‖ Consider referral if raised mean pulmonary artery pressure (≥25 mm Hg), PVR &gt;120 dynes/cm−5, PCWP &lt;15 mm Hg with clinical response to medical therapy</td>
</tr>
<tr>
<td>◀ Hereditary haemorrhagic Telangiectasia</td>
<td></td>
</tr>
<tr>
<td>◀ Ornithine transcarbamylase deficiency</td>
<td></td>
</tr>
<tr>
<td>◀ Glycogen storage disease: symptomatic or presence of hepatic adenoma(s)</td>
<td></td>
</tr>
<tr>
<td>◀ Primary hyperoxaluria: presence of renal impairment</td>
<td></td>
</tr>
<tr>
<td>◀ Porphryia</td>
<td></td>
</tr>
<tr>
<td>◀ Maple syrup urine disease</td>
<td></td>
</tr>
<tr>
<td>◀ Portopulmonary hypertension</td>
<td></td>
</tr>
</tbody>
</table>

*A variant syndrome is a patient with chronic liver disease whose UKELD score is <49.
†All patients with HCC should be managed within a Liver cancer MDT, which would be expected to recommend referral for liver transplantation as one of the potential ‘outcomes’.

AFP, alpha foetoprotein; ALD, alcoholic liver disease; CLD, chronic liver disease; HBV, hepatitis B virus; HCV, hepatitis C virus; NAFLD, non alcoholic fatty liver disease; PCWP, pulmonary capillary wedge pressure; PVR, pulmonary vascular resistance.
The quality and content of the referral can influence the pace of transplant assessment. This guide is not intended to be exhaustive, but ensures referrers provide critical information including: general investigations required prior to referral (online supplementary appendix 3); disease specific data required by LTU (online supplementary appendix 4) and comorbidities, psychosocial factors and addiction data that may inform the transplant assessment process (online supplementary appendix 5). All summarised in table 3.

**Considerations in patients with alcohol and drug-use disorders**

**Alcohol**

Best practice suggests that patients benefit from early referral to, and engagement with, local addiction services. Repeated non-adherence with documented advice to abstain from alcohol is an absolute contraindication to LT, so all discussions regarding the requirement for lifelong abstinence must be documented and the patient informed of the implication.

The UK Liver Advisory Group and National Institute for Health & Care Excellence (NICE) have recently updated the policies relating to referral of alcohol related liver disease (ArLD) patients for consideration of LT.

**Patients:**

► Who are alcohol dependent and continue drinking (even at reduced levels) should not be referred. Referral to alcohol services and engagement is mandatory.

► Who, after 3 months of validated abstinence, still have an indication for liver transplant, should be referred. Validation of abstinence includes random blood alcohol levels, alcohol metabolite testing and support from addiction services. Who are abstinent for <3 months, and positively engaged with addiction services, can be referred if there are issues (nutrition, frailty, etc) that might complicate the assessment, or death from liver disease may occur within 3 months.

Thus, there is no absolute rule governing the period of abstinence, other than patients must be abstinent at the time of referral. A pragmatic approach is to advise all patients with a failing liver due to alcohol, to become abstinent and engage with addiction services. If there is no immediate indication for referral for LT (as outlined in NICE guidance) then wait for 3 months to observe and if no improvement occurs, refer for LT. If, at 3 months, there is evidence of ongoing liver recovery, then a further 3-month deferment may optimise liver recovery, and also test the patient’s commitment to abstinence. At 6 months of abstinence, little further recovery can be expected and referral for LT is appropriate for any patient who remains in liver failure.

**Drug addiction/misuse**

Drug testing is part of the assessment for such patients. The use of prescribed methadone or buprenorphine replacement therapy does not preclude assessment for LT. However, current use of non-prescribed controlled drugs, addictive medications or ‘designer’ alternatives precludes referral.

**LT ASSESSMENT**

On receipt of a referral, the LTU determines whether the assessment requires urgent transfer, elective

---

**Table 3 Local investigations and key information to include in referral letter (more details in online supplementary appendices 3–5)**

<table>
<thead>
<tr>
<th>Comorbidity (include all details of pathologies, and important negatives)</th>
<th>Investigations (general investigations as below)</th>
<th>Disease-specific investigations</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cardiovascular</td>
<td>Chest X-ray</td>
<td>PSC: colonoscopy and recent liver imaging</td>
</tr>
<tr>
<td>Respiratory</td>
<td>ECG</td>
<td>Hepatitis B: screening tests and viral load</td>
</tr>
<tr>
<td>Renal</td>
<td>Echocardiogram</td>
<td>Liver transplantation</td>
</tr>
<tr>
<td>Bone</td>
<td>Oxygen Saturation</td>
<td>Hepatitis C: details of treatment</td>
</tr>
<tr>
<td>HIV</td>
<td>Analysis of Ascites</td>
<td>HCC: recent imaging and MDT discussions</td>
</tr>
<tr>
<td>Obesity</td>
<td>Endoscopy</td>
<td>PLD/PLKD: brain imaging for Berry aneurysms</td>
</tr>
<tr>
<td>Surgical/anaesthetic history</td>
<td>Nutritional assessment</td>
<td>Budd-Chiari syndrome: history of shunts.</td>
</tr>
<tr>
<td>Nutrition</td>
<td>Assessment of the performance status</td>
<td>Wilson’s disease: details of treatments</td>
</tr>
<tr>
<td>Metabolic syndrome</td>
<td>Up to date blood tests and UKELD</td>
<td>Encephalopathy: brain imaging, ammonia, number connection tests</td>
</tr>
<tr>
<td>Non-hepatic cancer</td>
<td>Adherence/addiction</td>
<td>Ascites: number of drains, episodes of SBP</td>
</tr>
<tr>
<td>Infectious disease</td>
<td></td>
<td>Alcohol related liver disease: period of abstinence, engagement with addiction services and so on</td>
</tr>
<tr>
<td>Social support</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Disabilities</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Alcohol and substance abuse</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mental health</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Smoking</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

AIH, Autoimmune Hepatitis; ArLD, Alcohol related Liver Disease; HCC, Hepatocellular Carcinoma; MDT, Multi Disciplinary Team; NG, Naso-gastric; NICE, National Institute for Health & Care Excellence; PBC, Primary Biliary Cholangitis; PLD/PLKD, Polycystic Liver Disease/Polycystic Liver & Kidney Disease; PSC, Primary Sclerosing Cholangitis; SBP, Spontaneous Bacterial Peritonitis; TC, Transplant Co-ordinator.
The aims of the liver transplant assessment are:
- To confirm the hepatological diagnosis.
- To confirm medical treatment has been optimised.
- To confirm that LT remains the most appropriate option.
- To evaluate mental and physical health comorbidities.
- To identify any contraindications.
- To ensure patients are fully informed of LT.

The transplant assessment is managed by the transplant coordinator (TC) and performed by the core MDT, consisting of physician, surgeon, anaesthetist, social worker, TC and dietician with additional input from pharmacist, addiction specialist, renal physician, oncologist and psychiatrist (see online supplementary appendix 6).

Transplant coordinator
The LT evaluation is supervised by the TC. The TC communicates directly with the patient and family/support network. This relationship evolves over the assessment process and beyond, depending on progress (figure 2). The TC gains invaluable insight into the candidate.

As up to 40% of assessments are declined, the TC’s role includes advising and supporting such individuals, especially those who assumed referral automatically implied acceptance onto the waiting list. For patients accepted onto the waiting list, the TC communicates with patient’s referring hospital, GP and community services. The TC provides an explanation of what patients can expect while waiting and when called in for LT.

Indications for LT
The transplant hepatologist confirms the primary liver condition (section 2), makes certain that medical treatment has been optimised, and ensures disease specific investigations are completed (see online supplementary appendices 3-5).

Table 4 describes absolute and relative contraindications to LT.

Table 4 Absolute and relative contra-indications to LT

<table>
<thead>
<tr>
<th>Absolute contraindications</th>
<th>Relative contraindications*</th>
</tr>
</thead>
<tbody>
<tr>
<td>Untreated HIV*</td>
<td>Inadequate social support</td>
</tr>
<tr>
<td>Severe extrahepatic disease with predicted mortality &gt;50% at 5 years including psychiatric disorder</td>
<td>Smoking</td>
</tr>
<tr>
<td>Severe irreversible pulmonary disease</td>
<td>Certain anatomical variants</td>
</tr>
<tr>
<td>Ongoing alcohol misuse</td>
<td>Extensive previous abdominal surgery</td>
</tr>
<tr>
<td>Active illicit drug use</td>
<td>BMI &gt;40 kg/m²</td>
</tr>
<tr>
<td>Certain anatomic variants</td>
<td>Poor clinic attendance and/or adherence</td>
</tr>
<tr>
<td>Ongoing extra-hepatic sepsis*</td>
<td>Active or previous extra-hepatic malignancy†</td>
</tr>
<tr>
<td>Liver cancer outside criteria*</td>
<td>LT is considered for patients with neuroendocrine tumours (requires referral to national panel).⁴⁶</td>
</tr>
</tbody>
</table>

*These contra-indications can be temporary and require discussion with LTU.

LTU is considered for patients with neuroendocrine tumours (requires referral to national panel).⁴⁶

BMI, body mass index; LT, liver transplant; LTU, liver transplant unit.

Indications of transplant assessment
MDT decisions
Following assessment, candidates are discussed at the MDT meeting with three potential outcomes: decline, defer, or accept. For those declined, the option of a second opinion, from another transplanting centre, is discussed with the patient and carers either by the hepatologist or the TC. Responsibility for such a further referral rests with the patient’s local physician or GP.

Some patients require further optimisation such as nutritional or cardio-respiratory input, prior to activation on the waiting list. Such ‘deferred’ patients require re-discussion, once the additional elements are addressed.
The remainder of assessments will be ‘accepted’ and placed on the LT waiting list. The option of live donation will be discussed, if appropriate.

Consent for LT
Consent for LT for candidates who retain mental capacity includes the general guidance for individuals undergoing any clinical intervention (see www.gmc-uk.org). However, the nature and risks of solid organ transplantation, means the process is more complex. Fuller guidance is given by the British Transplantation Society and National Health Service Blood and Transplant (https://bts.org.uk/wpcontent/uploads/2016/09/12_BTS_NHS_Consent_April_2013-I.pdf). LTU’s provide oral and written information concerning the risks and benefits of LT for patients and their carers, incorporating outcomes, donor organ related risks (infective, malignant, autoimmune, metabolic and others), procedure risks, disease recurrence and the need for adherence and life-long follow-up. The right to decline certain organs is carefully discussed (see Part 2, figure 1).

HOW TO MANAGE THE PATIENT ON THE WAITING LIST

Waiting list
During 2015–2016, 1161 patients joined the LT waiting list in the UK. At 1-year post-registration, 73% of patients had received a LT, 9% had died waiting or been removed due to deterioration. A further 4% were removed for other reasons such as clinical improvement, non-compliance or at patient’s request. The remaining 14% were still waiting.3

The waiting times depend on several factors, including recipient blood group, size and illness severity (i.e. UKELD score). The median waiting time is currently 135 days, though this is shorter for recipients who are blood group AB (56 days), A (84 days) and B (129 days) than blood group O (256 days).3 Details of organ allocation are outlined in Part 2.

Monitoring on the waiting list
Patients listed for LT must be monitored closely for changes in their clinical circumstances. The ‘local’ team manages all the patient’s routine care, but as this may impact on their suitability for LT, regular and careful communication with the LTU, via the TC is essential (see figure 2).

Optimisation of patients on the waiting list
Managing deterioration
Patients on the LT waiting list frequently present with decompensation to their referring hospital. This decompensation carries a significant mortality risk.20

The Lancet Standing Commission on Liver Disease has highlighted the need to focus on improving the care for acutely ill, hospitalised patients with liver disease.21 Ideally, hospitals should have in place a ‘care bundle’ for patients admitted with decompensated cirrhosis.22

Management of listed patients in the referring hospital
Patients on LT waiting list require monthly review in gastroenterology/hepatology outpatient clinics for nutritional review, blood-sampling, UKELD calculation and surveillance tests for cirrhosis. The LTU should be apprised of any deterioration, as listing status may need reviewing. Transfer to the LTU for acute deterioration is sometimes necessary, but if not, the confidence of patients and their carers is enhanced when there is open dialogue between the local hospital and the LTU.

Nutrition
Most patients with end-stage cirrhosis are malnourished23 and malnutrition in recipients predicts poorer outcome after LT.24 25 LTUs recommend a nutritional supplement for patients on the waiting list for the beneficial effect on anthropomorphic indices.26 Obesity is increasingly common among patients on the waiting list for LT. Sarcopenic obesity, or severe muscle depletion in the setting of obesity, is reported in almost half of obese patients with cirrhosis and is associated with an increased risk of pre-LT mortality. For patients with compensated cirrhosis, traditional lifestyle modifications are safe, but very low calorie diets (<1000 calories/day) are not safe. For decompensated cirrhotics, low-calorie diets may exacerbate sarcopenia and malnutrition, so such patients should maintain caloric intake with higher protein, nutrient-rich foods.27

Exercise
There is little data on exercise in patients waiting for LT. However, exercise programmes known as ‘prehabilitation’ can improve functional capacity and post-operative outcomes in patients with liver disease awaiting major surgery.28 Recently, the Birmingham group published a proposal to clarify this issue in patients awaiting LT.29 Most centres advise a sustained exercise target of up to 25 minutes daily, depending on the individual patients pre-existing activity levels and physical impairments. A step-counter (available as an app) is helpful for target setting and the Birmingham team’s proposal also incorporates specific advice on functional resistance exercise training that can readily be carried out at home.29

Other lifestyle factors
Lifestyle factors are central to survival both on the waiting list and beyond. Patients should be supported to make positive and sustainable lifestyle behaviour changes.

Active engagement with alcohol services is key for any ArLD patient and this may be a condition for listing. Alcohol use rates of 15%–25% have been reported for patients on LT waiting lists so ongoing monitoring (blood, urine, breath or hair) and support are essential.30 Most centres require random testing
for patients listed for ArLD and will liaise with the local hospital to facilitate timing and frequency.

Active smoking increases all-cause mortality at 5 and 10 years after LT \(^{31}\) due to additional surgical complications, more cardiovascular disease, sepsis and solid-organ malignancy. \(^{33-34}\) Smokers must engage in a smoking cessation programme and if smoking cessation is a condition for listing, patients should expect carbon monoxide breath-testing.

**Psychosocial support**

Patients listed for LT have high rates of psychological distress and depression which reduces quality of life, adaptive coping and functional status. \(^{35}\) Significant depression reduces pretransplant survival. \(^{36}\) Waiting times, concern about deterioration, organ scarcity and false-alarm contribute to patient anxiety. All patients require screening for depression and management accordingly.

Patients and carers receive education, including attendance at patient information sessions at the time of listing. This should include access to ‘expert patients’ information on LT services, the patient pathway, support groups and services offering psychological, social and spiritual/cultural support. The LTU have a transplant healthcare professional available 24/7 for telephone advice for patients and carers and ongoing contact with TC, specialist nurses and a social worker, as necessary.

**PALLIATIVE CARE AND LT**

Liver transplantation is the gold standard treatment for many patients with ALF, CLF and liver cancer, however, almost half of those assessed are declined and 20% patients die while waiting, meaning four people die for every one transplanted. Patients with CLD have a variable level of access to palliative care services, which can vary in quality. \(^{37-38}\)

By definition, those listed for LT have advanced disease and therefore, concomitant physical and psychosocial issues. Patients suffer from a high physical symptom burden \(^{39-40}\); symptoms are often complex and dramatic, frequently necessitating hospital admission \(^{41}\) with a poor evidence base to support the use of many drugs. Patients also suffer complex psychosocial issues including the stigma of liver disease, complex socioeconomic background circumstances and uncertainty associated with the potential for re-compensation and the possibility of transplantation.

Maintaining hope while ensuring an appropriate holistic assessment of the patient’s needs is challenging for everyone involved in delivering care. Discussions on end-of-life care including preferences, is an essential component in the management of patients with advanced liver disease, including those awaiting LT.

Early palliative care intervention can improve quality of life by improving symptom burden and mood, alongside less aggressive treatment and a reduction in hospitalisation. \(^{42-43}\) An assessment of palliative care needs should form an integral part of any transplant assessment process. Collaborative working is essential at a time of such great uncertainty if the overall quality of life for these patients and their carers is to be improved.

**CONCLUSIONS**

- All patients with decompensated CLD, should be considered for LT.
- All ALF patients should be discussed with the LTU and transferred in timely fashion, if appropriate.
- LT may be considered for variant syndromes, HCC and various other non-liver failure indications after discussion with LT team.
- The LTU require details of diagnosis, comorbidity, nutritional status and frailty in order to complete evaluation.
- Patients on the LT waiting list are shared between the referring centre and LTU. Good communication between the various healthcare professionals is critical. For patients who deteriorate, candid discussions with individuals and their relatives coupled with timely utilisation of palliative care services should optimise outcome for all concerned.

**Author affiliations**

1. Department of Hepatology, York Teaching Hospitals NHS Foundation Trust, York, UK
2. Pharmacy department, King’s College Hospital NHS Foundation Trust, London, UK
3. South West Liver Unit, Plymouth Hospitals NHS Trust, Plymouth, UK
4. Liver Unit, University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK
5. Department of Cellular Pathology, University of Birmingham, Birmingham, UK
6. Department of Hepatology, York Teaching Hospitals NHS Foundation Trust, York, UK
8. Department of Hepatology, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK
9. Liver Unit, The Newcastle Upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, UK
10. Liver Transplantation & HPB Surgery, King’s College Hospital NHS Foundation Trust, London, UK
11. Liver Transplantation & HPB surgery, University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK
12. Liver Unit, University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK

**Key points**

- Consider all patients with decompensated CLD for liver transplantation
- Discuss all ALF patients with LTU
- Provide LTU with details of primary liver disease and co-morbidities in mental & physical health
- Patients on transplant waiting list are the shared responsibility of referrer and LTU
- The palliative care needs of the patient are a critical part of the transplant assessment process.
Liver Transplantation & HPB Surgery, Leeds Teaching Hospitals NHS Trust, Leeds, UK
Pharmacy department, York Teaching Hospitals NHS Foundation Trust, York, UK
Palliative Care Medicine, King’s College Hospital NHS Foundation Trust, London, UK
Liver Transplantation Service, Royal Free London NHS Foundation Trust, London, UK
Scottish Liver Transplant Unit, Royal Infirmary of Edinburgh, Edinburgh, UK
Department of Hepatology, Royal Free London NHS Foundation Trust, London, UK
Department of Hepatology, Royal Free London NHS Foundation Trust, London, UK
Liver Unit, University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK

Acknowledgements Two individuals, Ms Lorna Tong and Mrs Elizabeth Crawshaw, read the manuscripts and offered critique as ‘expert patients’ and the authors are grateful for their critical input. The authors are thankful to Ms Robyn Southeran from the Medical Illustration department at York Hospital NHS FT.

Contributors There were 20 authors involved in the production of these two articles concerning liver transplantation. The original project was divided into an introduction, nine sections and a conclusion. From that original outline, the sections were written by writing groups and then collated. The nine sections were then divided into two halves for the purposes of publication, after discussion with the editors of FG. Each contributor provided editing input, to the project, as the manuscript went through its many iterations. The specific contribution/participation of each contributor are as follows: CM (consultant hepatologist in a DGH): senior author. Initiated section divisions, collected manuscripts. Contributed to writing by adding DGH aspects to all part 1 and management of post-transplant patient section. Edited all tables and overviewed the process. CM is responsible for overall content as guarantor. A Considine is a consultant pharmacist. She co-wrote the section on the Immunosuppression agents in Part 2 with Prof Neuberger and gave input into Part 1 particularly with the ‘disease specific considerations’ and where medication interactions can occur. MC (consultant transplant hepatologist): Co-authored the section on ‘Management of the patient on the waiting list’ and then read both Part 1 and 2 of final submission as an additional critique for all sections. Critical role in planning and acquisition of data for inclusion into guideline, along with evaluation of relevance to project. Final manuscript editing and approval. AH (consultant transplant hepatologist) wrote the section on ‘When to refer’ in Part 1, but also gave valuable oversight into Part 2 from point of view of medication and drug interactions, particularly with viral hepatitis treatment. Critical role in evaluating data for inclusion into guideline, along with maintenance of relevance to project. Final manuscript editing and approval. DT (consultant transplant hepatologist) co-authored the section on ‘Post-transplant surgical complications’. He also provided input into Part 1 and 2 from point of view of medication and drug interactions, particularly with viral hepatitis treatment. Critical role in evaluating data for inclusion into guideline, along with maintenance of relevance to project. Final manuscript editing and approval. AP (Liver Pharmacist) contributed to the PHV, and especially the section on PPHV, with an emphasis on medication interactions, particularly with viral hepatitis treatment. Critical role in evaluating data for inclusion into guideline, along with maintenance of relevance to project. Final manuscript editing and approval. DM (consultant transplant surgeon) contributed the section on Transplant surgical complications with KM and SH contributed the section on Post-Transplant Immunosuppression with the aid of A Considine. Prof Neuberger also contributed to the Part 1 in editorial role, when he helped with the original concept, he provided a critical role following the original guideline production and prior to it’s splitting into two halves (Part 1 and 2) and ensuring correct focus was maintained when the manuscript was reduced in size. DP (consultant transplant surgeon) wrote the section on organ allocation and donation. He also made a significant contribution to the post-operative care and complications sections and the pre-op evaluation (Part 1). Critical role in planning and acquisition of data for inclusion into guideline, along with evaluation of relevance to project. Final manuscript editing and approval. DM (consultant transplant surgeon) contributed the section on ‘Management of the patient on the waiting list’ and then read both Part 1 and 2 of final submission as an additional critique for all sections. Critical role in planning and acquisition of data for inclusion into guideline, along with evaluation of relevance to project. Final manuscript editing and approval. DT and RW (consultant transplant hepatologists) co-authored the section on Transplant surgery with KM and SH. Their contribution in Part 2 was proof-reading and providing critical input. Critical role in planning and acquisition of data for inclusion into guideline, along with evaluation of relevance to project. Final manuscript editing and approval. DT also supported the entire process by helping the section to a more manageable section. Ensuring relevance of data collected for the project along with final manuscript editing and approval. KM (consultant transplant surgeon) contributed to the section in Part 2 on Transplant surgery and outcomes. KM also provided input in Part 1 into section on Transplant assessment and previous surgery. Critical role in planning and acquisition of data for inclusion into guideline, along with evaluation of relevance to project. Final manuscript editing and approval. KM (consultant transplant surgeon) co-authored the section on Transplant surgery with KM and SH. Their contribution in Part 2 was proof-reading and providing critical input. Critical role in planning and acquisition of data for inclusion into guideline, along with evaluation of relevance to project. Final manuscript editing and approval. KM also provided input in Part 1 into section on Transplant assessment and previous surgery. Critical role in planning and acquisition of data for inclusion into guideline, along with evaluation of relevance to project. Final manuscript editing and approval.

Funding The authors have not declared a specific grant for this research from any fund agency in the public, commercial or not-for-profit sectors.

Competing interests None declared.

Patient consent for publication Not required.

Provenance and peer review Not commissioned; externally peer reviewed.
REFERENCES


